Evidence map›Paper›PMID 41272161›Full record

ArticleCommunications medicine2025

Genomic monitoring and tracking of mpox virus clade Ib in Burundi between july to september 2024.

Néhémie Nzoyikorera, Leonard Schuele, David F Nieuwenhuijse, Cassien Nduwimana, Théogène Ihorimbere, Denis Niyomwungere, Hayley Cassidy, Marjan Boter, Celestin Nibogora, Armstrong Ndihokubwayo and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Néhémie NzoyikoreraNational Reference Laboratory, National Public Health Institute, Bujumbura, Burundi. nzoyikorera@yahoo.fr.ORCID http://orcid.org/0000-0002-0971-2245
Leonard SchueleDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands.ORCID http://orcid.org/0000-0003-1721-5879
David F NieuwenhuijseDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands.ORCID http://orcid.org/0000-0003-1310-5031
Cassien NduwimanaNational Reference Laboratory, National Public Health Institute, Bujumbura, Burundi.
Théogène IhorimbereNational Reference Laboratory, National Public Health Institute, Bujumbura, Burundi.
Denis NiyomwungereNational Reference Laboratory, National Public Health Institute, Bujumbura, Burundi.
Hayley CassidyDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands.
Marjan BoterDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands.
Celestin NibogoraNational Reference Laboratory, National Public Health Institute, Bujumbura, Burundi.
Armstrong NdihokubwayoNational Reference Laboratory, National Public Health Institute, Bujumbura, Burundi.ORCID http://orcid.org/0009-0001-4547-9188
Alexis NiyomwungereOrganisation mondiale de la Santé, Bujumbura, Burundi.
Dionis NizigiyimanaNational Public Health Institute, Ministry of Public Health and the Fight against AIDS, Bujumbura, Burundi.
Marie Noelle UwinezaNational Reference Laboratory, National Public Health Institute, Bujumbura, Burundi.
Idrissa DiawaraMohammed VI University of Sciences and Health, Mohammed VI Higher Institute of Biosciences and Biotechnologies (UM6SS), Casablanca, Morocco.
Saria OtaniResearch Group for Genomic Epidemiology, National Food Institute, Technical University of Denmark, Kgs, Lyngby, Denmark.
Frank M AarestrupResearch Group for Genomic Epidemiology, National Food Institute, Technical University of Denmark, Kgs, Lyngby, Denmark.ORCID http://orcid.org/0000-0002-7116-2723
Marion KoopmansDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands.ORCID http://orcid.org/0000-0002-5204-2312
Joseph Nyandwi *National Public Health Institute, Ministry of Public Health and the Fight against AIDS, Bujumbura, Burundi.
Bas B Oude Munnink *Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince the first identification of mpox virus (MPXV) clade Ib in Burundi in July 2024, Burundi is one of the most affected countries in this evolving outbreak outside of the DRC.

methodsHere we aimed to understand the route(s) of introduction and spread of MPXV throughout the first months of the outbreak in Burundi. In total, 98 genome sequences from cases diagnosed during the first three months of the outbreak were generated.

resultsHere we show using phylogenetic analysis that the virus was introduced from the DRC and Bayesian evolutionary analysis shows that different clusters could be identified in Burundi leading to further spread within the country.

conclusionsIn summary, we identify sustained circulation of clade Ib MPXV in Burundi, most likely after several different introductions from the bordering province of South Kivu-DRC. The virus has acquired several additional APOBEC-3 mediated mutations, in line with reported evidence of ongoing human-to-human transmission.

Identifiers

PMID41272161
PMCPMC12639094

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.